|
1
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pinzani V, Bressolle F, Haug IJ, Galtier
M, Blayac JP and Balmès P: Cisplatin-induced renal toxicity and
toxicity-modulating strategies: A review. Cancer Chemother
Pharmacol. 35:1–9. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hartmann JT and Lipp HP: Toxicity of
platinum compounds. Expert Opin Pharmacother. 4:889–901. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsumura Y and Maeda H: A new concept for
macromolecular therapeutics in cancer chemotherapy: Mechanism of
tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI
|
|
6
|
Maeda H and Matsumura Y: EPR effect based
drug design and clinical outlook for enhanced cancer chemotherapy.
Adv Drug Deliv Rev. 63:129–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishiyama N and Kataoka K: Preparation and
characterization of size-controlled polymeric micelle containing
cis-dichlorodiammineplatinum(II) in the core. J Control Release.
74:83–94. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uchino H, Matsumura Y, Negishi T, Koizumi
F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S and Kakizoe
T: Cisplatin-incorporating polymeric micelles (NC-6004) can reduce
nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer.
93:678–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Levi F, Hrushesky WJ, Borch RF, Pleasants
ME, Kennedy BJ and Halberg F: Cisplatin urinary pharmacokinetics
and nephrotoxicity: A common circadian mechanism. Cancer Treat Rep.
66:1933–1938. 1982.PubMed/NCBI
|
|
10
|
Mizumura Y, Matsumura Y, Hamaguchi T,
Nishiyama N, Kataoka K, Kawaguchi T, Hrushesky WJ, Moriyasu F and
Kakizoe T: Cisplatin-incorporated polymeric micelles eliminate
nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer
Res. 92:328–336. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Plummer R, Wilson RH, Calvert H, Boddy AV,
Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, et
al: A Phase I clinical study of cisplatin-incorporated polymeric
micelles (NC-6004) in patients with solid tumours. Br J Cancer.
104:593–598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yanagihara K, Takigahira M, Takeshita F,
Komatsu T, Nishio K, Hasegawa F and Ochiya T: A photon counting
technique for quantitatively evaluating progression of peritoneal
tumor dissemination. Cancer Res. 66:7532–7539. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Booka E, Imamura CK, Takeuchi H, Hamamoto
Y, Gomi D, Mizukami T, Ichiyama T, Tateishi K, Takahashi T,
Kawakubo H, et al: Development of an S-1 dosage formula based on
renal function by a prospective pharmacokinetic study. Gastric
Cancer. 19:876–886. 2016. View Article : Google Scholar : PubMed/NCBI
|
